JUL 22, 2026 · REGULATORY APPROVAL
FDA approval: Jideytro (Type 1 - New Molecular Entity)
U.S. Food and Drug Administration
FDA approval of a new molecular entity (zidesamtinib) represents a regulatory action; the record does not contain clinical trial data or efficacy evidence.
Reported
Approval date2026-07-22
Formulations approved25 mg and 100 mg tablets, oral